Literature DB >> 19212424

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

S Funke1, I C Schneider, S Glaser, M D Mühlebach, T Moritz, R Cattaneo, K Cichutek, C J Buchholz.   

Abstract

We pseudotyped HIV-1 vectors with cytoplasmic tail-truncated envelope glycoproteins of a wild-type (WT) measles virus (MV). The particles entered the lymphatic cells exclusively through the signaling lymphocyte activation molecule (SLAM, CD150), whereas particles pseudotyped with the MV vaccine strain glycoproteins also recognized the ubiquitous membrane cofactor protein (CD46) as receptor and had less specific cell entry. MV(WT)-HIV vectors reached titers of 10(8) t.u. ml(-1), which were up to 10-fold higher than those of MV(Vac)-HIV vectors, and discriminated between SLAM-positive and SLAM-negative cells, also in mixed cell cultures. As these vectors transduce primary human cells more efficiently than vesicular stomatitis virus-G pseudotyped vectors do, they are promising candidates for gene transfer to human lymphocytes and certain epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212424     DOI: 10.1038/gt.2009.11

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

1.  The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.

Authors:  Markus Kalla; Christine Göbel; Wolfgang Hammerschmidt
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

2.  Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Authors:  Antonio Trabalza; Ioanna Eleftheriadou; Argyro Sgourou; Ting-Yi Liao; Petros Patsali; Heyne Lee; Nicholas D Mazarakis
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

3.  Specific retrograde transduction of spinal motor neurons using lentiviral vectors targeted to presynaptic NMJ receptors.

Authors:  I Eleftheriadou; A Trabalza; S M Ellison; K Gharun; N D Mazarakis
Journal:  Mol Ther       Date:  2014-03-26       Impact factor: 11.454

4.  Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.

Authors:  Tanner S Miest; Koon-Chu Yaiw; Marie Frenzke; Johanna Lampe; Andrew W Hudacek; Christoph Springfeld; Veronika von Messling; Guy Ungerechts; Roberto Cattaneo
Journal:  Mol Ther       Date:  2011-05-24       Impact factor: 11.454

5.  Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells.

Authors:  J-M Humbert; C Frecha; F Amirache Bouafia; T H N'Guyen; S Boni; F-L Cosset; E Verhoeyen; F Halary
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

6.  Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors.

Authors:  Cecilia Frecha; Camille Lévy; Caroline Costa; Didier Nègre; Fouzia Amirache; Robin Buckland; Steven J Russell; François-Loïc Cosset; Els Verhoeyen
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

7.  Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Authors:  Brigitte Anliker; Tobias Abel; Sabrina Kneissl; Juraj Hlavaty; Antonio Caputi; Julia Brynza; Irene C Schneider; Robert C Münch; Helga Petznek; Roland E Kontermann; Ulrike Koehl; Ian C D Johnston; Kari Keinänen; Ulrike C Müller; Christine Hohenadl; Hannah Monyer; Klaus Cichutek; Christian J Buchholz
Journal:  Nat Methods       Date:  2010-10-10       Impact factor: 28.547

8.  Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.

Authors:  Patrick L Sinn; Jeremy E Coffin; Natarajan Ayithan; Kathleen H Holt; Wendy Maury
Journal:  Methods Mol Biol       Date:  2017

9.  Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Authors:  Katharina M Uhlig; Stefan Schülke; Vivian A M Scheuplein; Anna H Malczyk; Johannes Reusch; Stefanie Kugelmann; Anke Muth; Vivian Koch; Stefan Hutzler; Bianca S Bodmer; Axel Schambach; Christian J Buchholz; Zoe Waibler; Stephan Scheurer; Michael D Mühlebach
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

Review 10.  A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Authors:  Thomas Wirth
Journal:  World J Exp Med       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.